Compare JPMorgan Chase & Co (JPM) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Spyre Therapeutics Inc. Common Stock — how do they compare? JPMorgan Chase & Co trades at $338.38 (market cap $890.37B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: JPMorgan Chase & Co is far larger — about 121.1× Spyre Therapeutics Inc. Common Stock's market cap, and JPMorgan Chase & Co pays a 1.97% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Chase & Co for 127 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| JPM | SYRE | |
|---|---|---|
Market Cap | $890.37B | $7.35B |
Volume | 10,236,412 | 1,624,631 |
Sector | Financials | Health |
52-Week High | $365.18 | $108.92 |
52-Week Low | $282.84 | $22.18 |
Typical Hold Time | 127 Days | 0 Days |
Enterprise Value | $1.40T | $6.35B |
Dividend Yield | 1.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase (JPM) trades at $331.43, down 0.86% on the day, with a bearish technical signal despite strong fundamentals. The company reported mixed Q3 2026 earnings but beat expectations in Q1 and Q2, with revenue growing to $181.85B in 2025. Analyst consensus remains positive with a $373.36 price target, though technical indicators show resistance near $336-339 levels.
JPMorgan offers solid investment potential with strong profitability (33.38% net margin) and attractive valuation (P/E 13.9), but faces headwinds from negative cash flow trends and geopolitical risks highlighted in recent CEO warnings. The stock's current technical weakness suggests near-term consolidation before potential upside toward analyst targets.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
